ERIM
BCLI

Eagle Ridge Investment Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Eagle Ridge Investment Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-667
Closed -$45K – 55
2015
Q1 		$45K Buy
+667
New +$42.2K 0.02% 56

Other funds holding BCLI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
M&T Bank
M&T Bank Buffalo, New York $34.1B AUM 29.2% 1-Year Est. Return

Eagle Ridge Investment Management's BCLI Position: Q2 2015 in Review

Eagle Ridge Investment Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2015, closing a stake of 667 shares — an estimated $45K sold.

Eagle Ridge Investment Management first reported a position in BCLI in Q1 2015 and held it in 1 quarter. The position peaked at $45K in Q1 2015. 20 funds tracked by Wall St. Rank hold BCLI as of Q2 2015.

  • Eagle Ridge Investment Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2015 after selling out during the quarter.
  • Eagle Ridge Investment Management sold 667 BRAINSTORM CELL THERAPUTC shares in Q2 2015, an estimated $45K.
  • Eagle Ridge Investment Management first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2015 and held it in 1 quarter.
  • Eagle Ridge Investment Management's BRAINSTORM CELL THERAPUTC position peaked at $45K in Q1 2015.
  • 20 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2015.

Based on Eagle Ridge Investment Management's 13F filing for Q2 2015, filed 21 Jul 2015.